Abstracts tagged "autoantibodies"

Abstract Number: 1930 • 2015 ACR/ARHP Annual Meeting
Identification of a Broadly Immunogenic Prevotella Copri T Cell Epitope in Patients with Rheumatoid Arthritis
Annalisa Pianta¹, Elise E. Drouin¹, Sheila Arvikar², Klemen Strle¹, Jameson T. Crowley¹, Qi Wang³, Catherine E. Costello³ and Allen C. Steere⁴, ¹Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, MA, ⁴Center for Immunolgy and Inflammatory Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Specific microorganisms in the gut microbiome may have a pathogenic role in rheumatoid arthritis (RA). Recently, Scher et al. showed that Prevotella copri, an…
Abstract Number: 3100 • 2015 ACR/ARHP Annual Meeting
Anti-RA33 Citrullinated/Native Double-Reactive Antibodies Identify Patients with the Highest Risk of Radiographic Progression in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against RA33 (hnRNP A2/B1) were one of the earliest antigen specificities identified in rheumatoid arthritis (RA). Unlike the erosive disease associated with anti-citrullinated…
Abstract Number: 447 • 2015 ACR/ARHP Annual Meeting
Components of Treatment Delay in Rheumatoid Arthritis Differ According to Autoantibody Status
Arthur G Pratt¹, Ben Hargreaves², Dennis W Lendrem², Osman Aslam² and John D Isaacs², ¹Institute of Cellular Medicine (Musculoskeletal Research Group), National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom, ²Institute of Cellular Medicine (Musculoskeletal Research Group), NIHR Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Despite a proliferation of early arthritis (EA) clinics intended to expedite the diagnosis of rheumatoid arthritis (RA), patients continue to experience substantial and multifactorial…
Abstract Number: 1121 • 2015 ACR/ARHP Annual Meeting
Breach of B Cell Anergy in New Zealand Black Congenic Mice
Kieran Manion^1,2, Yuriy Baglaenko^1,2, Nan-Hua Chang³ and Joan Wither³, ¹Immunology, University of Toronto, Toronto, ON, Canada, ²Genetics and Development, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada
Background/Purpose: Anti-DNA B cells are a primary cause of pathology in individuals with systemic lupus erythematosus (SLE), producing autoantibodies that deposit in diverse tissues and…
Abstract Number: 2021 • 2015 ACR/ARHP Annual Meeting
Omega-3 Fatty Acids Are Associated with a Lower Prevalence of Autoantibody Positivity in HLA-DR Shared Epitope Positive Subjects Who Are at Increased Risk for Future RA
Ryan W. Gan¹, M. Kristen Demoruelle², Kevin D. Deane³, Michael H. Weisman⁴, Jane H. Buckner⁵, Peter K. Gregersen⁶, Ted R. Mikuls⁷, James R. O'Dell⁷, Richard M. Keating⁸, Tasha Fingerlin⁹, Gary O. Zerbe¹⁰, Michael J. Clare-Salzler¹¹, V. Michael Holers¹² and Jill M. Norris¹³, ¹Colorado School of Public Health, University of Colorado Denver, Aurora, CO, ²Rheumatology, University of Colorado School of Medicine, Aurora, CO, ³Division of Rheumatology, U Colo Denver, Aurora, CO, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Feinstein Insititute for Medical Research, Manhasset, NY, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Division of Rheumatology, Scripps Health, La Jolla, CA, ⁹National Jewish Health, Denver, CO, ¹⁰Biostatistics and Informatics, Colorado School of Public Health / University of Colorado Anschutz Medical Campus, Aurora, CO, ¹¹Experimental Pathology, University of Florida, College of Medicine, Gainesville, FL, ¹²Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, ¹³University of Colorado Denver, Aurora, CO
Background/Purpose: Studies of fish intake suggest that omega-3 fatty acids (n-3 FAs) could be protective against the development of RA. Previously, we found n-3 FAs…
Abstract Number: 3115 • 2015 ACR/ARHP Annual Meeting
Autoantibodies of the IgA Type a Link Between the Gut and the Anti-TNF Therapy Response in Rheumatoid Arthritis Patients Analysed in Two Clinical Trials
Zoltan Konthur¹, Ute Nonhof², Melvin Michael Wiemkes³, Jacqueline Detert³, Tanja Braun⁴, Jörg Hollidt², Gerd Burmester⁵ and Karl Skriner⁵, ¹Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany, ²Drug Response DX GmbH, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Germany, Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: So far no mechanism for non response to biologicals targeting TNFα has been described despite one third of rheumatoid arthritis patients treated are non-responders.…
Abstract Number: 528 • 2015 ACR/ARHP Annual Meeting
RA33 Challenges the Paradigm of Autoantigen Selection in Rheumatoid Arthritis
Maximilian F. Konig¹, Jon Giles², Peter A. Nigrovic³ and Felipe Andrade¹, ¹Division of Rheumatology, The Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Columbia University Medical Center, NY, NY, ³Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Antibodies against citrullinated proteins (ACPAs) are the autoimmune hallmark of rheumatoid arthritis (RA), and can precede the onset of symptomatic disease by years. By…
Abstract Number: 1209 • 2015 ACR/ARHP Annual Meeting
Associations Between Rheumatoid Arthritis (RA)-Related Autoimmunity, Joint Symptoms, and Physical Activity in First-Degree Relatives without RA in a Prospective Cohort
Jan M. Hughes-Austin¹, Joachim H. Ix², Samuel R. Ward³, Michael H. Weisman⁴, James R. O'Dell⁵, Ted R. Mikuls⁵, Jane H. Buckner⁶, Peter K. Gregersen⁷, Richard M. Keating⁸, Kevin D. Deane⁹, V. Michael Holers¹⁰ and Jill M. Norris¹¹, ¹Department of Family and Preventive Medicine, University of California, San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA, ³Radiology, Orthopaedic Surgery, and Bioengineering, University of California, San Diego, La Jolla, CA, ⁴Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁷Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Med Res, Manhasset, NY, ⁸Division of Rheumatology, Scripps Health, La Jolla, CA, ⁹Division of Rheumatology, U Colo Denver, Aurora, CO, ¹⁰Rheumatology Division, Univ of Colorado School of Med, Aurora, CO, ¹¹University of Colorado Denver, Aurora, CO
Background/Purpose: Physical activity in RA patients is significantly less than in counterparts without RA, and many live just above the muscle strength threshold needed for…
Abstract Number: 2034 • 2015 ACR/ARHP Annual Meeting
Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Barbara Goldstein¹, Jeffery J. Swigris², Shannon Kasperbauer¹, Pearlanne Zelarney¹ and JoAnn Zell¹, ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: National Jewish Health (NJH) is a tertiary referral center for pulmonary and immunologic disease. The infectious disease division at NJH specializes in the care…
Abstract Number: 3260 • 2015 ACR/ARHP Annual Meeting
Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: A Eustar Multicentre Study
Maria Grazia Lazzaroni¹, Enrico Colombo², Ilaria Cavazzana¹, Oliver Distler³, Rucsandra Dobrota³, Jasmin Eisenring³, Roger Hesselstrand⁴, Lazlo Czirjak⁵, Cecilia Varju⁵, Gabriella Nagy⁵, Vanessa Smith⁶, Paola Caramaschi⁷, Valeria Riccieri⁸, Eric Hachulla⁹, Katarzyna Romanowska-Próchnicka¹⁰, Alexandra Balbir-Gurman¹¹, Emmanuel Chatelus¹², Ana Carolina Araújo¹³, Yannick Allanore¹⁴, Paolo Airò¹⁵ and EUSTAR , ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Rheumatology and Clinical Immunology Unit, University and Spedali Civili of Brescia, Brescia, Italy, ³Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, Sweden, ⁵University of Pécs Medical Center, Pécs, Hungary, ⁶Rheumatology, Ghent University Hospital, Ghent, Belgium, ⁷Rheumatology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy, ⁸Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, ⁹Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ¹⁰Department of Pathophysiology, Medical University of Warsaw and Department of Connective Tissue Diseases, Institute of Rheumatology, Warsaw, Poland, ¹¹B. Shine Rheumatology Unit, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel, ¹²Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Serviço de Medicina 2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ¹⁴Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, ¹⁵Rheumatology and Clinical Immunology Unit, Spedali Civili of Brescia, Brescia, Italy
Increased Frequency of Malignancies Synchronous to the Onset of Systemic Sclerosis in Anti-RNA Polymerase III Antibodies Positive Patients: a EUSTAR Multicentre Study Background/Purpose: Several clinical issues…
Abstract Number: 543 • 2015 ACR/ARHP Annual Meeting
The IL-20 Receptor Axis in Early Rheumatoid Arthritis: Novel Inflammation-Independent Links Between Autoantibody Positivity and Radiographic Progression
Tue Wenzel Kragstrup^1,2,3, Stinne Greisen¹, Morten Aagaard Nielsen¹, Chris Rhodes², Kristian Stengaard-Pedersen³, Merete Lund Hetland⁴, Kim Hørslev-Petersen⁵, Peter Junker⁶, Mikkel Østergaard⁷, Malene Hvid^1,8, Thomas Vorup-Jensen¹, William H. Robinson^2,9, Jeremy Sokolove^2,10 and Bent Deleuran^1,3,8, ¹Department of Biomedicine, Aarhus University, Aarhus, Denmark, ²VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴DANBIO, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁵Rheumatology, Rheumatology King Christian X's Hospital, Graasten, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁸Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁹Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹⁰Stanford University School of Medicine, Stanford, CA
Background/Purpose: Rheumatoid arthritis (RA) is often characterized by the presence of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and bone erosions. Successful treatment can compromise…
Abstract Number: 1210 • 2015 ACR/ARHP Annual Meeting
Genetic, Environmental, and Serologic Risk Factors for Inflammatory Joint Signs Among First-Degree Relatives without Rheumatoid Arthritis in a Prospective Cohort
Jeffrey A. Sparks¹, Shun-Chiao Chang², Kevin D. Deane³, Ryan W. Gan⁴, Kristen Demoruelle³, Marie L. Feser³, LauraKay Moss³, Jane H. Buckner⁵, Richard M. Keating⁶, Karen H. Costenbader⁷, Peter K. Gregersen⁸, Michael H. Weisman⁹, Ted R. Mikuls¹⁰, James R. O'Dell¹⁰, V. Michael Holers³, Jill M. Norris⁴ and Elizabeth W. Karlson², ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁴Epidemiology, Colorado School of Public Health, Aurora, CO, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁶Division of Rheumatology, Scripps Health, La Jolla, CA, ⁷Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁸Feinstein Insititute for Medical Research, Manhasset, NY, ⁹Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Family history of RA in a first-degree relative increases RA risk 4-fold. Determining risk factors for inflammatory joint signs (IJS) in this high risk…
Abstract Number: 2076 • 2015 ACR/ARHP Annual Meeting
Development of Lupus Nephritis: Preclinical Evaluation of Patients Who Subsequently Develop Systemic Lupus Erythematosus Demonstrate Elevation of Select Soluble Mediators Prior to and at Disease Classification in Patients with Nephritis
Melissa E. Munroe¹, Jourdan R. Anderson¹, Julie M. Robertson¹, Timothy B. Niewold², George C. Tsokos³, Michael P. Keith⁴, Joan T. Merrill⁵, Jill P. Buyon⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Walter Reed National Military Medical Center, Bethesda, MD, ⁵Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁷Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁸Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a heterogeneous autoimmune disease marked by immune dysregulation and a spectrum of pathogenic autoantibodies. Why some patients have only moderate symptoms and…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 1363 • 2015 ACR/ARHP Annual Meeting
Changes in Cyclooxygenase-2’s Expression, and PGE2’s and 6-Keto-PGF1α Levels in the Presence of the Muscarinic Acethylcholine Receptor Antibody in Primary Sjogren Syndrome
Micaela Ana Cosatti¹, Silvia Reina², Cecilia N. Pisoni³, Alicia Eimon⁴, Sabrina Ganzinelli² and Enri Borda², ¹Section Rheumatology and Immunology, CEMIC, CABA, Argentina, ²Pharmacology Unit, School of Dentistry, University of Buenos Aires, Buenos Aires, Argentina; National Research Council of Argentina (CONICET), Buenos Aires, Argentina, ³Lupus Research Unit, The Rayne Institute, St Thomas' Hospital and Kings College London, London, United Kingdom, ⁴CEMIC, Buenos Aires, Argentina
Background/Purpose: to assess the inflammatory process provoked by the M3 muscarinic acetylcholine receptor antibody from primary Sjogren Syndrome (pSS) patient’s sera in rat submandibular gland…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].